Jupiter Neurosciences Signs Up to $100 Million Deal for Exclusive U.S. Rights to Psychedelic MDMA Formulation

Rua Bioscience Limited and PharmAla Biotech Holdings Inc. announced that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement under which Rua will import, distribute and sell PharmAla's pharmaceutical-grade LaNeo MDMA in New Zealand. The agreement follows Medsafe's approval on 4 September 2026 of two psychiatrists to prescribe pharmaceutical-grade MDMA for post-traumatic stress disorder, making New Zealand only the second country, after Australia, to allow authorised psychiatrists to prescribe MDMA. Rua will supply PharmAla's 40 mg LaNeo MDMA capsules, manufactured to good manufacturing practice standards, to authorised prescribers in New Zealand, with the first shipment supplied on a consignment basis so Rua can enter the market with minimal upfront capital. PharmAla also announced that on September 1, 2026, PharmAla Biotech Inc. and JC Logistics Ltd t/a Veridion Group signed a termination and mutual release agreement ending, by mutual consent, their exclusive New Zealand distribution and license agreement dated September 21, 2025; Veridion held no PharmAla inventory, purchase orders or regulatory registrations, and no amounts are payable by either party in connection with the termination. Rua Chief Executive Officer Paul Naske said the deal adds a new product category to the business and positions Rua early in a field expected to grow, while PharmAla Chief Executive Officer Nicholas Kadysh said Rua has the licences, quality systems and prescriber relationships to deliver a reliable, GMP-grade supply from day one.